'use client';
import React from 'react';

const C_MarketOpportunity: React.FC = () => {
  return (
    <>
      <h2 className="roboto-slab-medium text-xl text-gray-dark mb-8 mt-4">
        Market Opportunity Overview
      </h2>

      <p className="roboto-slab-light text-base mb-10 mt-12 leading-relaxed">
        <strong>A Transformative Moment in Drug Discovery.</strong> The AI-driven drug discovery market is surging, with industry estimates placing its value at approximately $500 million in 2020 and projecting a compound annual growth rate of around 40%. By the late 2020s, this market could expand to between $3 and $5 billion. For companies that can reduce costly failures and optimize therapeutic efficacy, the premium subscription fees commanded by these tools promise a substantial return on investment.
      </p>

      <p className="roboto-slab-light text-base mb-10 leading-relaxed">
        <strong>Focusing on Disease Pathways, Not Chemistry.</strong> At Zeroshot Biolabs, our core competency lies in deciphering complex transcriptomic landscapes to understand disease mechanisms and predict therapeutic responses. We are not a chemical structure design company. Instead, our strength is in identifying key disease pathways—enabling us to discover protein targets or even repurpose existing drugs based on deep biological insights. This fundamental focus positions us uniquely in the market, ensuring that every insight we generate is grounded in robust, systems-level biology.
      </p>

      <p className="roboto-slab-light text-base mb-10 leading-relaxed">
        <strong>The SaaS Revolution in Drug Discovery.</strong> Our Software-as-a-Service platform is designed to provide unparalleled transcriptomic analysis that empowers biotech companies and academic institutions to make data-driven decisions. By catching potential failures early and fine-tuning therapeutic strategies with high precision, our platform will save our clients hundreds of millions of dollars in R&D costs. With this proven value, we anticipate commanding premium subscription fees in a market that is already rapidly scaling.
      </p>

      <p className="roboto-slab-light text-base mb-10 leading-relaxed">
        <strong>Drug Candidate Development and Licensing.</strong> Following a model reminiscent of the Schrödinger Nimbus Takeda story, we envision developing select drug candidates to a compelling proof-of-concept stage, then licensing or selling these assets to major pharmaceutical companies. This approach allows us to concentrate on our core competency—AI-driven preclinical confidence—while benefiting from lucrative deals in the "$100 million batch" range, along with milestone payments and royalties. This pathway offers a highly attractive revenue stream without requiring us to engage directly in chemical design.
      </p>

      <p className="roboto-slab-light text-base mb-10 leading-relaxed">
        <strong>Unlocking the Power of Drug Repurposing.</strong> Our advanced transcriptomic models can conduct an 'all-versus-all' match of drug-gene interactions across hundreds of disease contexts. This unique capability positions us to identify promising candidates for drug repurposing—leveraging existing safety and pharmacokinetic data to accelerate clinical timelines from the typical 7–10 years down to 3–5 years. By quickly pinpointing new therapeutic opportunities, we not only enhance clinical value but also significantly mitigate development risk.
      </p>

      <p className="roboto-slab-light text-base mb-10 leading-relaxed">
        <strong>A Proven Market Blueprint.</strong> The success story of Schrödinger Nimbus Takeda serves as a powerful validation of our approach. By focusing on in-depth disease pathway analysis and harnessing AI for robust preclinical predictions, this model has demonstrated that high-value deals and effective drug repositioning strategies are well within reach. It clearly illustrates how a company can build significant market confidence and financial upside without deviating from its core scientific strengths.
      </p>

      <p className="roboto-slab-light text-base mb-10 leading-relaxed">
        <strong>A Clear Path Forward.</strong> Whether through our SaaS platform, targeted drug candidate development, or innovative drug repurposing strategies, Zeroshot Biolabs is uniquely positioned to redefine the landscape of drug discovery. Our commitment to leveraging transcriptomic insights to improve preclinical confidence paves the way for safer, more effective therapeutics and ultimately, a transformative impact on human health.
      </p>
    </>
  );
};

export default C_MarketOpportunity;
